Trial Profile
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CheckMate153
- Sponsors Bristol-Myers Squibb
- 19 Apr 2023 Results(n=58) assessing Changes in the genomic and neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab presented at the 114th Annual Meeting of the American Association for Cancer Research
- 03 Dec 2021 Status changed from active, no longer recruiting to completed.
- 20 May 2019 Results published in the Journal of Thoracic Oncology